Cochrane · systematic review · CD013851
Acetylcholinesterase inhibitors for autistic spectrum disorders
Ure, A, Cox, GR, Haslam, R, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
2
Included studies
NR
No studies 2 · 14.3%Ungraded 0 · 0%Very low 9 · 64.3%Low 3 · 21.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Galantamine plus risperidone compared to placebo plus risperidone for treatment of the core symptoms of autism spectrum disorder
Population: children and adolescents with a diagnosis of autism spectrum disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall autism features Not assessed Galantamine plus risperidone vs placebo plus risperidone | no estimate extracted | NR | No studies |
Social communication (Lethargy/Social withdrawal subscale of the ABC‐C; 0 to 64; lower = better) Galantamine plus risperidone vs placebo plus risperidone | no estimate extracted | 1 study · 40 participants | Very low Downgraded: imprecision, indirectness |
Repetitive and restricted behaviour (Stereotypical Behaviour subscale of the ABC‐C; 0 to 28; lower = better) Galantamine plus risperidone vs placebo plus risperidone | no estimate extracted | 1 study · 40 participants | Very low Downgraded: imprecision, indirectness |
Adverse events (Side Effects Checklist) Galantamine plus risperidone vs placebo plus risperidone | OR 5.57 [1.42, 21.86] | 1 study · 40 participants | Low Downgraded: imprecision |
Irritability (Irritability subscale of the ABC‐C; 0 to 60; lower = better) Galantamine plus risperidone vs placebo plus risperidone | no estimate extracted | 1 study · 40 participants | Low Downgraded: imprecision |
Hyperactivity (Hyperactivity subscale of the ABC‐C; 0 to 64; lower = better) Galantamine plus risperidone vs placebo plus risperidone | no estimate extracted | 1 study · 40 participants | Low Downgraded: imprecision |
General health and function Not assessed Galantamine plus risperidone vs placebo plus risperidone | no estimate extracted | NR | No studies |
Donepezil compared to placebo for treatment of core symptoms of autism spectrum disorder
Population: children and adolescents with a diagnosis of autism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall autism features (total score of RLRS; raw score means; lower = better) Donepezil vs placebo | no estimate extracted | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
Social communication (Social Relationships subscale of RLRS; raw score means; lower = better) Donepezil vs placebo | no estimate extracted | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
Repetitive and restricted behaviour (Sensory Motor subscale of RLRS; raw score means; lower = better) Donepezil vs placebo | no estimate extracted | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events (Side Effects Checklist) Donepezil vs placebo | no estimate extracted | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
Irritability (Child Behaviour Checklist Oppositional Defiant Disorder Subscale; lower = better) Donepezil vs placebo | no estimate extracted | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
Hyperactivity (Child Behaviour Checklist Attention problems Subscale; lower = better) Donepezil vs placebo | no estimate extracted | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
General health and function (Severity of Illness subscale of Clinical Global Impression Scale; lower = better) Donepezil vs placebo | no estimate extracted | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |